Company profile
Vericel Corporation
NASDAQ: VCEL · Healthcare · Biotechnology
#258 of 1,418 Healthcare companies by revenue62nd-percentile growth
EA Score
83B+FH 85DQ 83GM 73SS 86
v0.1 · 65/100 weight · provisional
↑ Piotroski F, Altman-Z · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$292.1M
Rev growth YoY (TTM)
+22.4%
Net income (FY)
$16.5M
Employees
398
as of 2026-08-08
Market cap
$2.3B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$276.3M$276.3M2025
Net income$16.5M$16.5M2025
Operating income$11.0M$11.0M2025
Total assets$488.0M$488.0M2025
Liabilities$133.3M$133.3M2025
Equity$354.6M$354.6M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
MACI Implants And Kits100%
By geography
Not disclosed.
The read
What is Vericel Corporation’s revenue?
Vericel Corporation booked $276.3M in FY2025 revenue, growing 16% year over year — faster than most Healthcare companies we track, at a 6.0% net margin.
Peers · Healthcare
Xeris Biopharma Holdings, Inc.64CAurinia Pharmaceuticals Inc.78B+Adaptive Biotechnologies Corporation68BHarrow Health, Inc.73BViemed Healthcare, Inc.75B+Vireo Growth Inc.59CNeighbors
Middlesex →Key facts
CEODominick C. Colangelo
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: VCEL
Employees398
IPO date1997-02-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.